Colon carcinoma: Consensus of therapeutic strategies;Das kolonkarzinom: Konsens der therapeutischen strategien

Internist

Volumn 41, Issue 9, 2000, Pages 876-885

  Graeven, U ^a   Schmiegel, W ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; COLON CARCINOMA; DRUG INFUSION; DRUG RESPONSE; HUMAN; REVIEW; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROURACIL; GERMANY; HUMANS; INCIDENCE; LEUCOVORIN; LYMPHATIC METASTASIS; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; PRODRUGS;

EID: 0033830984     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050640     Document Type: Review

References (46)

1. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult
2. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer
3. Kolorektales karzinom: Pravention und fruherkennung in der asymptomatischen bevolkerung - Vorsorge bei risikogruppen - Endoskopische diagnostik, therapie und nachsorge von polypen und karzinomen
4. Adjuvant therapy of colorectal cancer: Why we still don't know
5. Post operative adjuvant chemotherapy or BCG for colon cancer: Results from NSABP protocol C-01
6. Levamisole and fluorouracil for adjuvant therapy of resected colon cancer
7. The benefit of leucovorin-modulated fluorouracil a postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowl Project Protocol C-03
8. The benefit of leucovorin-modulated fluorouracil a postoperative adjuvant therapy for primary colon cancer: Results from National Surcical Adjuvant Breast and Bowl Project Protocol C-03
9. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer
10. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
11. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer
12. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamosole in patients with Dukes B and C carcinoma of the colon: Results from National Surcical Adjuvant Breast and Bowl Project Protocol C-04
13. Fluoruracil (FU) leucovorin (LV) and levamosole (LEV) adjuvant therapy for colon cancer: Five-year final report of INT-0089
14. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer
15. Comparative efficacy of adjuvant chemotherapy in patients with Dukes B versus Dukes C colon cancer: Results from four National Surgical Adjuvant Breast and Bowl Project Protocol studies (C-01, C-02, C-03, and C-04)
16. Portal vein chemotherapy fot colorectal cancer: A meta-analysis of 4000 patients in 10 studies
17. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: A randomised trial
18. Active specific immunotherapy for stage II and III human colon cancer: A randomized trial
19. Adjuvant active specific immunotherapiy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5483
20. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma
21. Monoclonal antibody therapy for resected Dukes C colorectal cancer: Seven-year outcome of a multicenter randomized trial
22. Surgery for recurrent coloncancer: Strategies for identifying resectable recurrence and success rates after resection
23. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer
24. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma
25. Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: A prospective randomized trial
26. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continous infusion for advanced colorectal cancer: A French Intergroup Study
27. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma
28. A randomized phase III study comparing weekly folinic acid (FA) and high-dose 5-fluorouracil (5-FU) with monthly 5-FU/FA (days 1-5) in untreated patients with metastatic colorectal cancer
29. Efficacy of intravenous continous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
30. Weekly 24 h infusion of high-dose (HD) S-fluorouracil with or without folinic acid (FA) vs. bolus 5-FU7FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): A randomized phase III study of the EORTC GITCCG and the AIO
31. Capecitabine - A novel oral tumor-activated fluoropyrimidine
32. A phase III trial (SO14796) of Xeloda (Capecitabine) in previously untreated advanced/metastatic colorectal cancer
33. A phase III trial (SO 15695) of Xeloda (Capecitabine) in previously untreated advanced/metastatic colorectal cancer
34. Randomized comparative study of ORZEL (oral uracil/tegafur UTF) plus leukovorin (LV) versus perental 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer
35. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluoruracil failure for patients with metastatic colorectal cancer
36. Randomised trial of irinotecan versus fluouracil by continous infusion after fluouracil failure in patients with metastatic colorectal cancer
37. Weekly irinotecan (CPT-11), leucovorin (LV) and fluorouracil (FU) is superior to daily LV/5-FU in patients (pts) with previously untreated metastatic colorectal cancer (CRC)
38. A randomized phase III trial comparing Irinotecan (IRI) + S-FU/folinic acid (FA) to the same schedule of S-FU/FA in patients (pts) with metastatic colorectal cancer (MCRC) as front line chemotherapy (CT)
39. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
40. Oxaliplatin with high-dose leucovorin and 5-FU 48-hour continuos infusion in pretreated metastatic coloractal cancer
41. Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer
42. A randomized trial of leucovorin and 5-fluorouracil with or without oxaliplatin in advanced colorectal cancer
43. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusionla chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery